CAMP
Income statement / Annual
Last year (2025), CAMP4 Therapeutics Corp.'s total revenue was $3.50 M,
an increase of 436.50% from the previous year.
In 2025, CAMP4 Therapeutics Corp.'s net income was -$80.40 M.
See CAMP4 Therapeutics Corp.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
11/30/2023 |
02/28/2023 |
02/28/2022 |
02/28/2021 |
02/29/2020 |
02/28/2019 |
02/28/2018 |
02/28/2017 |
| Operating Revenue |
$3.50 M |
$652.00 K |
$350.00 K |
$294.95 M |
$295.84 M |
$308.59 M |
$366.11 M |
$363.80 M |
$365.91 M |
$351.10 M |
| Cost of Revenue |
$1.64 M
|
$0.00
|
$0.00
|
$185.94 M
|
$173.95 M
|
$186.18 M
|
$222.80 M
|
$216.04 M
|
$215.02 M
|
$207.75 M
|
| Gross Profit |
$1.86 M
|
$652.00 K
|
$350.00 K
|
$109.01 M
|
$121.89 M
|
$122.41 M
|
$143.30 M
|
$147.76 M
|
$150.89 M
|
$143.35 M
|
| Gross Profit Ratio |
0.53
|
1
|
1
|
0.37
|
0.41
|
0.4
|
0.39
|
0.41
|
0.41
|
0.41
|
| Research and Development Expenses |
$38.20 M
|
$38.82 M
|
$40.62 M
|
$24.57 M
|
$28.44 M
|
$25.81 M
|
$29.44 M
|
$27.66 M
|
$25.76 M
|
$22.01 M
|
| General & Administrative Expenses |
$17.36 M
|
$14.92 M
|
$11.61 M
|
$51.82 M
|
$52.33 M
|
$49.08 M
|
$57.67 M
|
$31.07 M
|
$52.09 M
|
$55.90 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$47.39 M
|
$48.56 M
|
$46.20 M
|
$60.53 M
|
$49.89 M
|
$50.10 M
|
$49.04 M
|
| Selling, General & Administrative Expenses |
$17.36 M
|
$14.92 M
|
$11.61 M
|
$99.21 M
|
$100.90 M
|
$95.28 M
|
$118.20 M
|
$80.96 M
|
$102.19 M
|
$104.95 M
|
| Other Expenses |
-$1.64 M
|
$0.00
|
$0.00
|
$9.92 M
|
-$2.44 M
|
-$403.00 K
|
$12.32 M
|
-$672.00 K
|
$445.00 K
|
-$101.00 K
|
| Operating Expenses |
$53.92 M
|
$53.74 M
|
$52.23 M
|
$133.70 M
|
$134.76 M
|
$125.87 M
|
$159.96 M
|
$120.05 M
|
$142.94 M
|
$142.01 M
|
| Cost And Expenses |
$55.56 M
|
$53.74 M
|
$52.23 M
|
$319.63 M
|
$308.71 M
|
$312.05 M
|
$382.76 M
|
$336.09 M
|
$357.96 M
|
$349.76 M
|
| Interest Income |
$2.17 M
|
$1.33 M
|
$2.81 M
|
$989.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$6.26 M
|
$5.19 M
|
$5.82 M
|
$20.10 M
|
$16.73 M
|
$10.28 M
|
$9.90 M
|
| Depreciation & Amortization |
$1.64 M
|
$1.70 M
|
$1.68 M
|
$0.00
|
$22.80 M
|
$22.00 M
|
$31.99 M
|
$20.02 M
|
$22.96 M
|
$23.47 M
|
| EBITDA |
-$50.42 M |
-$51.39 M |
-$50.20 M |
-$25.08 M |
-$2.64 M |
$8.47 M |
$15.22 M |
$47.05 M |
$31.36 M |
$24.71 M |
| EBITDA Ratio |
-14.41
|
-78.82
|
-143.43
|
-0.09
|
-0.01
|
0.03
|
0.04
|
0.13
|
0.09
|
0.07
|
| Operating Income Ratio |
-14.88
|
-81.42
|
-148.23
|
-0.08
|
-0.05
|
-0.02
|
-0.05
|
0.05
|
0.02
|
0
|
| Total Other Income/Expenses Net |
-$28.34 M
|
$1.30 M
|
$2.59 M
|
-$6.65 M
|
-$1.87 M
|
-$1.64 M
|
-$41.55 M
|
$12.87 M
|
$31.03 M
|
$1.59 M
|
| Income Before Tax |
-$80.40 M
|
-$51.79 M
|
-$49.29 M
|
-$31.34 M
|
-$30.06 M
|
-$20.60 M
|
-$58.32 M
|
$23.86 M
|
$28.71 M
|
-$6.97 M
|
| Income Before Tax Ratio |
-22.99
|
-79.43
|
-140.83
|
-0.11
|
-0.1
|
-0.07
|
-0.16
|
0.07
|
0.08
|
-0.02
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$1.15 M
|
$1.09 M
|
$561.00 K
|
$20.45 M
|
-$1.33 M
|
$10.68 M
|
-$1.10 M
|
| Net Income |
-$80.40 M
|
-$51.79 M
|
-$49.29 M
|
-$32.49 M
|
-$27.99 M
|
-$56.31 M
|
-$78.77 M
|
$18.40 M
|
$16.62 M
|
-$7.15 M
|
| Net Income Ratio |
-22.99
|
-79.43
|
-140.83
|
-0.11
|
-0.09
|
-0.18
|
-0.22
|
0.05
|
0.05
|
-0.02
|
| EPS |
-2.65 |
-2.66 |
-4.07 |
-0.9 |
0 |
0 |
-2.35 |
0.53 |
0.47 |
-0.2 |
| EPS Diluted |
-2.65 |
-2.66 |
-4.07 |
-0.9 |
0 |
0 |
-2.34 |
0.52 |
0.46 |
-0.2 |
| Weighted Average Shares Out |
$30.38 M
|
$19.51 M
|
$12.12 M
|
$36.13 M
|
$1.53 M
|
$1.50 M
|
$33.48 M
|
$34.59 M
|
$35.25 M
|
$35.92 M
|
| Weighted Average Shares Out Diluted |
$30.38 M
|
$19.51 M
|
$12.12 M
|
$36.13 M
|
$1.53 M
|
$1.50 M
|
$33.67 M
|
$35.29 M
|
$36.14 M
|
$35.92 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
